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Clinical use of analytical tests to assess genomic variants in circulating tumor 
DNA (ctDNA) is on the rise. This joint review from the American Society of Clinical 
Oncology and College of American Pathologists summarizes current information about 
clinical ctDNA assays and provides a framework for future research.  
 
Methods 
An expert Panel conducted a literature review on the use of ctDNA assays for 
solid tumors, including pre-analytical variables, analytical validity, interpretation and 
reporting, and clinical validity and utility. 
 
Results 
The literature search identified 1338 references. Of those, 390 plus 30 
references supplied by the Panel were selected for full-text review. There were 77 
articles selected for inclusion.  
 
Conclusion 
The evidence indicates that testing for ctDNA is optimally performed on plasma 
collected in cell stabilization or EDTA tubes, with EDTA tubes processed within 6 hours 
of collection. Some ctDNA assays have demonstrated clinical validity and utility with 
certain types of advanced cancer; however, there is insufficient evidence of clinical 
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validity and utility for the majority of ctDNA assays in advanced cancer. Evidence shows 
discordance between the results of ctDNA assays and genotyping tumor specimens and 
supports tumor tissue genotyping to confirm undetected results from ctDNA tests. There 
is no evidence of clinical utility and little evidence of clinical validity of ctDNA assays in 
early stage cancer, treatment monitoring, or residual disease detection. There is no 
evidence of clinical validity and clinical utility to suggest that ctDNA assays are useful 
for cancer screening, outside of a clinical trial. Given the rapid pace of research, re-
evaluation of the literature will shortly be required, along with the development of tools 
and guidance for clinical practice.  
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The use of assays that assess genomic variants in circulating tumor DNA, 
designated as ctDNA assays throughout this manuscript, are on the rise in the oncology 
clinical setting, despite uncertainties around pre-analytical considerations, analytical 
validity, and clinical validity and utility. The American Society of Clinical Oncology 
(ASCO) and College of American Pathologists (CAP) convened a joint Panel of 
oncology and pathology experts (refer to Data Supplement Appendix A) to review 
available evidence and develop this review about ctDNA assays as a cancer biomarker 
in various clinical scenarios. This joint review is intended to provide an assessment of 
the evidence on ctDNA assays in oncology and a framework for future research and 
clinical practice guidelines to help better inform clinical practice.  
The review is limited to analysis of variants in ctDNA for solid tumors and the 
analysis of sequence or copy number variants in DNA. The following topic areas are 
addressed: 1) pre-analytical variables, 2) analytical validity, 3) interpretation and 
reporting, and 4) clinical validity and utility.  
 
Methodology 
Literature review. A literature search was completed on March 20, 2017. The 
search strategies were developed in collaboration with a medical librarian for the 
concepts of: liquid biopsies; blood; cancer abnormalities; and pre-analytic, analytic, 
interpretation, reporting, utility, and validity variables. (Refer to Data Supplement 
Appendix B for details.) The Panel supplemented the search with additional articles, in 
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particular, to cover areas not targeted by the literature search. As noted in the 
QUOROM diagram in Data Supplement Figure B1, a total of 1338 unique publications 
were identified in the search and 390 articles were selected for full text review. The 
Panel supplied an additional 30 references. Ultimately, 77 articles were selected for 
inclusion in the manuscript.  
Writing and review. The Panel was divided into four writing groups to review the 
evidence relevant to the four topic areas. The entire Panel was involved in the evidence 
review and development of the manuscript. External reviewers provided comments on 
the draft manuscript. Table 1 describes the terms and definitions that were applied. 
More detailed explanations, definitions, and examples are provided in the respective 
sections. The manuscript was reviewed and approved by ASCO and CAP leadership. A 
listing of findings regarding the current status of ctDNA testing in patients with solid 
tumors is provided in Table 2.   
 
BACKGROUND 
   
The term “liquid biopsy” was coined nearly a decade ago by Pantel and Alix-
Panabières to imply the use of a blood test to provide the same diagnostic information 
included in a tissue biopsy. 1 Compared to a classic biopsy, liquid biopsies are more 
convenient and present minimal procedural risk to the patient (Table 3). Further, their 
collection is less expensive. Therefore, they can be performed on a serial basis. In 
theory, liquid biopsies may also deliver more complete information regarding the 
patient’s entire tumor burden as it theoretically represents all tumor DNA present in the 
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circulation, as opposed to the spatial limitations of a biopsy sampling of a single lesion 
within a single anatomic site. 
The term “liquid biopsy” can include measurement of soluble factors, such as 
proteins tumor markers (e.g., carcinoembryonic antigen), circulating tumor cells (CTC), 
and circulating cell free nucleic acids.  This manuscript focuses on the recent advances 
in molecular technology that have facilitated detection and quantification of cancer-
related genomic variants in the cell-free DNA, which are thought to reflect ctDNA. 2 The 
literature regarding ctDNA assays is rapidly growing, but the synthesis of this 
information is cumbersome due to broad variability in definitions, analytical approaches, 
and assessment of clinical significance. 
 Three semantic terms are critical to the assessment of clinical significance, first 
proposed by the Evaluation of Genomic Applications in Practice and Prevention 
(EGAPP) Initiative of the Centers for Disease Control with regard to genetic testing 3, 
and later adopted and refined by a panel of the Institute of Medicine 4; analytical validity, 
clinical validity, and clinical utility. Analytical validity refers to the ability of a test to 
accurately and reliably detect the variant(s) of interest and includes measures of 
accuracy, sensitivity, specificity, and robustness. Clinical validity implies that the test 
may accurately detect the presence or absence of a pathologic state or predict 
outcomes for groups of patients whose test results differ. Clinical utility is documented 
when high levels of evidence exist to demonstrate that the use of the test improves 
patient outcomes compared to not using it. 
 To determine clinical validity or utility, one must define the intended use of the 
marker. In broad terms, but specific to cancer, possible uses may include categorization 
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for risk of disease, screening unaffected patients for the disease, differential diagnosis 
of a proven malignancy, prognosis in the absence of further treatment, prediction that a 
specific treatment is likely to be effective, and monitoring disease activity – either to 
detect impending recurrence in a patient presumed free of disease or to determine 
whether a patient with known cancer has evidence of progressive disease. In solid 
tumors, the latter few uses may differ in implications, depending on the stage of the 
disease (i.e., early vs. advanced/metastatic). 
 
PRE-ANALYTICAL VARIABLES FOR ctDNA SPECIMENS  
 
Pre-analytical variables for ctDNA include all steps preceding analysis of the 
specimen. The variables inherent in these steps may affect the quality of the specimen 
and its fitness for cell-free DNA extraction and ctDNA testing. 5,6 Pre-analytical variables 
that increase degradation of cell-free DNA in the specimen, or increase contamination 
of the plasma with normal DNA from leukocytes, are the most likely to compromise 
analytical success.  
 
Optimal Specimen Type 
Current evidence suggests that the optimal specimen type for analysis of ctDNA 
in blood is plasma. Both serum and plasma consist of the liquid, cell-free fraction of 
whole blood. The major difference between them is that serum is devoid of clotting 
factors. 
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The concentration of total cell-free DNA (normal and ctDNA) from identical blood 
samples is higher in serum compared to plasma. Most cell-free DNA in blood results 
from leucocyte lysis occurring during clotting. 7 The amount of normal DNA derived from 
leukocyte lysis, which dilutes the ctDNA, is much lower in plasma, especially if it is 
separated from the leucocyte fraction soon after the blood draw or if the blood is drawn 
into collection tubes containing a leucocyte stabilizer. 8,9 
 
Specimen Collection 
Blood draw. The majority of published studies include little detail on the blood 
draw procedure. Blood is typically acquired from peripheral veins, but no data currently 
exist on the comparative effects on ctDNA analysis of specimen acquisition from other 
sites (e.g., central veins, either directly or from an intravascular port, or arteries) or other 
blood draw variables (e.g., use of a discard tube, tube fill level, tube inversions, and 
draw order). In the absence of these data, the phlebotomist should follow the tube 
manufacturer’s instructions for use. 
Tube type and specimen handling. The type of blood collection tube is the 
most commonly studied pre-analytical variable. Standard lavender top tubes containing 
the anti-coagulant K2EDTA are suitable for cell-free DNA specimen collection. A critical 
consideration with the use of K2EDTA tubes is that time-to-processing should be as 
expedient as possible within 6 hours from collection, to avoid lysis of white blood cells, 
which can dilute the ctDNA with normal leukocyte DNA. 10-13 The use of leukocyte 
stabilization tubes allows greater flexibility in the time-to-processing of up to 48 hours, or 
longer with some tubes, without compromise of ctDNA detection or quantification. 
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7,10,12,14-16 However, a head-to-head performance comparison of all tube types used for 
blood collection for ctDNA analysis has not been reported.  
Once peripheral blood is collected, it is typically processed through filtration or a 
sequential pair of centrifugations at low-speed and high-speed. 9-12 The significant 
excess of white cells compared to ctDNA in peripheral blood underscores the 
importance that either filtration or the first, low-speed centrifugation step occurs within 
hours of collection in EDTA tubes to minimize leukocyte lysis. 
The influence of storage temperature and time on unprocessed whole blood has 
been variable and this issue remains unresolved. Studies have shown up to a 10-fold 
increase in levels of DNA, reflecting leukocyte lysis, from tubes with stabilizing agents 
stored for 3 to 5 days refrigerated or warmed to 40°C. 10,14,17 There has also been at 
least one report that plasma volume decreases by greater than 1 mL when unprocessed 
tubes with stabilizing agents are stored refrigerated or warmed. 15 
There is consensus among studies that storage of frozen plasma prior to DNA 
extraction has no effect on subsequent ctDNA analysis. However, studies indicate that 
plasma must be isolated before freezing, and freezing unspun whole blood should not 
be performed. Although exposure of plasma to a single freeze-thaw cycle does not 
affect downstream ctDNA analysis, multiple freeze-thaw cycles may result in nucleic 
acid degradation and decreased ability to detect ctDNA. 5,12 Therefore, current evidence 
suggests that processed plasma be aliquoted into single-use fractions for future ctDNA 
extraction and analysis. 
Transport. Shipping exposes samples to unfavorable handling and temperature 
conditions, such as agitation and extreme cold or hot temperatures. If plasma is 
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separated and frozen prior to shipping, studies generally kept the samples frozen to 
avoid freeze-thaw cycles. 5,12 Unprocessed samples requiring overnight shipping 
necessitate collection in tubes with stabilizing agents and packaging to maintain room 
temperature and minimize temperature fluctuations. 14 Although a recent study of 
agitation of samples in tubes with stabilizing agents did not detect altered ctDNA yield or 
genomic DNA release, 15 sample protection in secure foam boxes to reduce sample 
agitation is common practice. 
DNA purification. There are several different cell-free DNA purification methods, 
numerous different kits based on these methods, and various protocol modifications. 6 
These varying methods and modifications lead to a wide range of cell-free DNA 
purification approaches that may affect cell-free DNA yield and purity. Therefore, 
consideration of the tube type and other pre-analytical variables, as well as downstream 
analytical methods, may contribute to the optimal DNA purification approach. 
Knowledge gaps. Insufficient evidence exists to resolve major remaining 
questions regarding retrospective studies, and whether using archived serum or plasma 
not collected into leukocyte stabilization tubes or processed rapidly, accurately reflect 
clinical validity or utility, especially in terms of sensitivity of the assay for ctDNA. Little is 
known about the effects of different storage temperatures or duration on ctDNA assays. 
Therefore, while the presence of ctDNA suggests that the performance of the assay in 
such specimens might be feasible, it is unknown whether patients who are considered 
“negative” are truly negative, and whether serial values truly reflect increase or 
decrease of the biomarker.  
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Further, limited data are available regarding the impact of blood draw procedures 
and potentially confounding patient-related factors that may contribute to the release of 
cell-free DNA. These factors include diurnal or other biologic influences, smoking, 
pregnancy, exercise, and numerous nonmalignant disorders such as inflammatory 
conditions, anemia, heart disease, metabolic syndrome, and autoimmune disorders. 
Future studies would require banked specimens with well-documented pre-analytical 
variables and patient factors to address these limitations. 
 
ANALYTICAL VALIDITY  
 
Multiple assays and methods are available for ctDNA analysis, and they can be 
categorized into two general classes - those targeted for a single or small number of 
variants, and those aiming for broader coverage. 18 Targeted assays detect known 
recurring somatic variants and generally employ one of several PCR-based strategies, 
such as real-time or digital PCR. 19 Targeted assays are useful for detection of specific 
known variants, often at very low levels, in a single gene or small number of genes. 
These targeted assays are generally employed for select applications such as 
identification of variants that are associated with response to drugs in individual tumor 
types (e.g., EGFR variants in patients with non-small cell lung cancer [NSCLC]). In 
contrast to targeted assays, broad coverage assays generally employ next generation 
sequencing (NGS)-based approaches and have the capability of detecting a larger 
number of variants in multiple genes, often examining parts of >50 genes. Broader 
panels are usually designed to be applied to multiple different tumor types. Two different 
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ctDNA assays may or may not provide the same results due to different assay 
performance characteristics. For example, the assays may have different lower limits of 
detection, or they may interrogate different genomic regions. It is therefore not possible 
to assume that the assays are interchangeable, and to do so requires rigorous cross-
assay comparisons. 
The most commonly used approach for assessing analytical validity in published 
studies of ctDNA assays has been to compare concordance between variants detected 
in tumors and plasma. There are many biological factors that may affect concordance 
independent of analytical factors (e.g., tumor type, stage, tumor heterogeneity, time 
between tumor tissue and blood sampling, and whether the variant is clonal vs. sub-
clonal). 20-23 Consequently, analytical validity studies designed in this way may confound 
issues of analytical validity with issues of clinical validity. In a situation where a somatic 
variant is identified in a tumor tissue specimen but not by the ctDNA assay, or vice 
versa, it may be unclear whether this discordance is caused by analytical or biological 
factors. For applications such as detection of EGFR variants in NSCLC, concordance 
between tissue and plasma variant detection for leading platforms ranges from 70% to 
90%, with the positive predictive value of ctDNA assays being higher than the negative 
predictive value. 23-25  
To overcome the issues discussed above, future studies of analytical validity 
need to include evaluation of standardized samples, reference materials with known 
variants at specified variant allele fractions and variant copies per assay (e.g., EGFR 
p.T790M variant at 1%, with 10 variants per assay). These reference materials could 
include the use of cell lines, engineered cell lines or artificial DNA constructs diluted in 
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an appropriate matrix. Analytical validity is best determined within groups of specimens 
ranging through low, intermediate, and high levels of the analyte, and examination of 
analytical validity must include evaluation of both the wet laboratory and bioinformatics 
portion of an assay. Such reference materials allow assessment of the analytical 
performance of the assay independent of the potential biologic factors that confound 
comparisons between tumor and plasma specimens. Use of such reference materials 
has allowed documentation of the lower limit of detection for single variants ranging 
from <0.1% to >1%, depending on the assay. Given the low limits of detection required 
for ctDNA assays, it is critical that laboratories ensure validation studies clearly 
demonstrate their routine ability to detect variants near the reported lower limit of 
detection of their assay. However, optimal lower limits of detection for various types of 
somatic variants remain to be established. These lower limits of detection will vary 
depending on the intended use of the ctDNA assay, but they are likely at least two 
orders of magnitude lower than for tumor genotyping assays for some applications. 
Analytical specificity for assays has generally been shown to be >95%. 21 Cross-
platform comparisons have been undertaken in a few small studies, with high 
concordance between assays for specific variants with discrepancies largely explained 
by differences in analytical sensitivity among assays. 24,25 Few studies have examined 
cross-platform comparisons of broad NGS ctDNA assays. 
Future research in the area of analytical validity needs to focus on more and 
larger cross-platform comparisons in order to clearly define the performance of various 
assays. Additionally, more studies are urgently needed on assay robustness to changes 
in pre-analytic and analytic variables. In order to ensure quality control and to allow 
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unbiased comparison between assays, proficiency testing using standardized samples 
and administered by independent groups would be highly desirable, and several such 
efforts are in development. Finally, studies are needed to define the minimal levels of 
analytical sensitivity and specificity that will maximize clinical utility across the spectrum 
of envisioned clinical applications for ctDNA assays.    
 
INTERPRETATION AND REPORTING 
 
A comprehensive discussion of the interpretation and reporting content for ctDNA 
assay results is beyond the scope of this Statement. This section focuses on areas that 
present particular challenges to ctDNA assays. Previously published general guidance 
about interpretation and reporting of clinical molecular assays should be reviewed. 26-28  
Selection of therapy is a nuanced process guided by numerous factors, including 
tumor type, grade, stage, patient performance status, prior therapies, and genetic 
findings. The same variant may have different therapeutic consequences depending on 
the primary tumor site. Caution is needed when reporting actionability of a particular 
genomic variant on a ctDNA report, including: 1) in relation to general associations 
between a variant and potential therapy options in specific tumor types, 2) without 
specific therapeutic recommendations for the patient, and 3) while emphasizing that 
variant data must be integrated with other clinical information for appropriate selection 
of therapy. 
As is discussed in the above analytical validity section, targeted PCR-based 
ctDNA assays focus on the detection of known somatic variants. Broad NGS-based 
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approaches detect these somatic (acquired) variants, but they also may identify 
germline (heritable) variants. Evidence suggests that a variant is somatic if it meets 
certain criteria, including: 1) a variant allele fraction that is substantially less than 50%, 
which is the expected allele fraction for heterozygous germline variants, 2) the variant is 
a known commonly recurring somatic variant with clinical significance in cancer, and 3) 
the variant is not commonly observed in population databases. The presence of all 
three criteria strongly suggests that a variant is somatic, but there are ambiguous cases 
on rare occasions. High allele fraction alone does not strongly discriminate between 
somatic and germline, as some somatic variants in cell-free DNA may be found with 
high allele fraction (such as a variant allele from a locus that is genetically amplified). In 
cases where the variant could be germline in nature, follow-up testing of germline DNA 
with a clinical germline sequencing assay could aid clinical decision making (e.g., 
determination if a BRCA1 pathogenic or likely pathogenic variant is germline or 
somatic).  
The proportion of ctDNA as a fraction of total free DNA in plasma (may be 
referred to as “purity”) varies substantially between different patients, and allele 
fractions of variants in ctDNA need to be interpreted with great caution. The relative 
abundance of leucocyte DNA may vary in different specimens based on pre-analytical 
issues (as noted above).  Comparison of relative allele fractions between different 
variants identified in the same assay might identify variants that are not present in all 
cancer cells, identifying intra-patient tumor heterogeneity. 29 Such sub-clonal variants 
may have a lower response to therapies targeting the mutation, 30 although there is no 
evidence of validity for this approach and further research is required. Furthermore, it 
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can be difficult to calculate the actual fraction of cell-free DNA composed of ctDNA, 
especially with targeted assays. Although targeted assays can provide accurate 
quantitation of variant allele fraction, a single measurement may not be representative 
of the actual fraction of cell free DNA composed of ctDNA. For example, the variant 
could be sub-clonal or the variant could be present in a region of copy number variation 
(for example on an amplified allele). 
Not all somatic variants identified in circulating cell-free DNA originate from the 
cancer. Somatic variants may be found in apparently healthy people, 31,32 arising in part 
from clonal hematopoiesis. Age-related clonal hematopoiesis, also referred to as clonal 
hematopoiesis of indeterminate potential (CHIP), is characterized by the detection of 
recurring somatic variants most commonly associated with hematologic cancers in the 
peripheral blood. 33-36 These variants are observed with increasing frequency from 
approximately the fifth decade of life, detected in approximately 5% of persons 60-69 
years of age and 10% of persons 70 years of age or older. 33 The substantial majority of 
individuals with clonal hematopoiesis do not have hematologic cancer, but it does 
confer an increased risk. 31,32 The most commonly involved genes include DNMT3A, 
TET2, and ASXL1; however, other frequently mutated genes include TP53, JAK2, 
SF3B1, GNB1, PPM1D, GNAS, and BCORL1. 33-35 Although most studies examining 
CHIP have been performed with peripheral blood, these mutations also appear in 
plasma, 31,32 as hematopoietic cells are the origin of the majority of cell-free DNA in 
healthy individuals. 37 Given the limited evidence, caution is needed when interpreting 
ctDNA variants in these genes, and further work is needed to determine how to interpret 
and report ctDNA variants in these genes.  
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All ctDNA assays have an appreciable rate of discordance with tumor testing, 
and the ctDNA assay may not detect the variant observed in the tumor specimen in 
some patients. In part, this reflects very low release of tumor DNA into plasma in some 
patients with cancer. Such discordant results are particularly frequent in cancers of the 
central nervous system, 20 potentially as the blood brain barrier blocks release of tumor 
DNA into the systemic circulation. Failure to detect a somatic variant in a ctDNA assay, 
consequently, may result from the variant being absent in the tumor or from an 
insufficient amount of ctDNA being present in the specimen. In contrast, with standard 
tissue-based molecular testing in which histologic assessment of the specimen is used 
to evaluate for sufficient neoplastic cell content, similar confirmation of the presence of 
sufficient ctDNA is not generally available in ctDNA assays. For these reasons, 
reporting of ctDNA assays necessitates clear communication of this limitation when a 
somatic variant is not detected by including a prominent note or comment in the report. 
Terms such as “not detected,” “undetected,” or “uninformative,” are generally more 
precise than reporting the lack of detection of somatic variants as “negative.” 
 
CLINICAL VALIDITY AND UTILITY  
 
Once a tumor biomarker test has demonstrated adequate analytical validity, the 
next step is to demonstrate clinical validity and, most importantly, clinical utility. These 
elements are essential in order for clinicians and patients to use these tests to inform 
treatment decisions. While it is highly unlikely that a ctDNA test would have clinical 
utility if it has not previously been shown to have clinical validity, the reverse is not true. 
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An assay may have clinical validity but not have clinical utility. Demonstration of clinical 
validity does not confer or imply clinical utility. Several methods of establishing clinical 
utility have been proposed, either as prospective clinical trials, 38,39 or as retrospective 
characterization of archived specimens from previous prospective clinical trials. 40 For 
ctDNA assays, the pre-analytical issues discussed above render the latter particularly 
problematic, unless care has been taken to collect, process, and store the specimens 
appropriately. 
As noted, there are several contexts in which a ctDNA assay might be applied. 
We will principally focus on use of ctDNA assays in metastatic cancer, since there is 
generally substantially less evidence regarding ctDNA assays in other settings.  
 
Evidence on the Use of ctDNA Assays for Treatment Selection in Advanced 
Cancer 
The clinical validity of ctDNA assays has been the subject of multiple studies in 
select cancer types. In general, PCR-based assays for detection of oncogenic driver 
variants have very high diagnostic specificity, but more modest diagnostic 
sensitivity. For example, in lung cancer, a review of five studies that used tissue 
genotype as the reference standard, specificities for canonical driver variants averaged 
96% (95% CI, 83% to 99%), while sensitivities averaged 66% (95% CI, 63% to 69%). 41-
45 For variants selected prior to treatment, such as the EGFR T790M variant in the 
setting of acquired resistance, sensitivities remained moderate, while specificities 
showed more variability (range of 40% to 78%), a difference thought to be due to the 
genomic heterogeneity of treatment resistance. 30,46-49 PCR-based ctDNA assays for 
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KRAS genotyping in colorectal cancer have also been systematically analyzed and 
demonstrate high specificity and moderate sensitivity. 50  
Fundamentally, there are two paradigms to demonstrate clinical utility and the 
adoption of ctDNA as a clinically useful test. The most reliable are prospective clinical 
trials to test the clinical utility of ctDNA as a standalone diagnostic test. No such trial has 
been reported to date. A second strategy is to assess whether ctDNA provides the 
same information as tissue genomic evaluation. If tissue genomic evaluation has proven 
clinical utility with high levels of evidence, demonstrating that a ctDNA assay has high 
agreement with tumor tissue genotyping may provide sufficient evidence of utility for 
ctDNA assays in driving patient treatment decisions.  
Definitively establishing the clinical utility of ctDNA assays, as compared to a 
standard biopsy for tumor genotyping, is challenging because prospective trial data are 
lacking. At present, one PCR-based ctDNA assay for the detection of EGFR variants in 
patients with NSCLC has received regulatory approval in the United States and Europe, 
and PCR-based ctDNA assays for EGFR in NSCLC and KRAS in colorectal cancer are 
available for commercial use in Europe. These assays have demonstrated clinical 
validity, 51-53 but the clinical utility in this setting is based on retrospective analyses. 
Evidence demonstrated that, while positive EGFR testing results may effectively be 
used to guide therapy, “undetected” results should be confirmed with analysis of a 
tissue sample, if possible. Cases in which the variant is not detected in the ctDNA, but is 
detected in the tissue sample are relatively common, so “undetected” ctDNA assay 
results should be confirmed in tumor tissue testing (Figure 1. Reflex Tumor Testing)54. 
As a general point, the literature demonstrates that treatment selection in advanced 
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cancer is optimized when ctDNA assays are performed in the context of disease 
progression rather than while a patient is still demonstrating response to prior therapy. 
Circulating tumor DNA levels may fall when a tumor is responding to treatment, and 
sensitivity of ctDNA assays may be reduced if the samples are taken whilst a tumor is 
responding to therapy. 
The challenges of demonstrating clinical utility are illustrated in NSCLC. A major 
potential issue is that the patient population selected for study inclusion may not be 
representative of those targeted for the intended clinical use of the ctDNA assay. In 
NSCLC, this can occur for at least two reasons. First, although recent prospective data 
are lacking, older trials have estimated that approximately 20% of NSCLC patients with 
resistance to EGFR TKIs either cannot (or were not willing to) be biopsied or biopsy 
tissue was inadequate. 55 Although several trials have demonstrated that patients with 
NSCLC with an EGFR variant in plasma do just as well on EGFR TKI as those with an 
EGFR variant in the tumor,51,54,56 these studies did not include patients who could not 
obtain tumor tissue genotyping. Second, most trials preselected patients with positive 
tumor tissue genotyping for treatment; therefore, plasma positive cases often were 
“double positives” both in tumor tissue and plasma, which was not representative of the 
intended clinical use of ctDNA assays. One post-hoc analysis of an osimertinib trial in 
NSCLC included 18 patients with EGFR T790M detected in plasma but not in tumor 
tissue, and this small cohort of patients did less well than patients with T790M detected 
on tumor tissue genotyping. 30 To date, few trials have prospectively tested the 
outcomes of treatment when a targeted therapy was selected solely based upon a 
ctDNA assay result. 57 
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There is limited evidence of clinical validity of ctDNA analysis in other tumor 
types and for variants that were not analyzed as part of the ctDNA studies for EGFR in 
lung cancer and KRAS in colorectal cancer. A wide range of ctDNA assays have been 
developed and clinically studied for detection of potentially targetable variants such as 
BRAF variants in melanoma 58 and PIK3CA and ESR1 variants in breast cancer, 29,59 
and the diagnostic performance characteristics are in line with the assays described 
previously. Nevertheless, the clinical utility of these assays has not been established. 
The large number of potential genetic driver events in advanced cancers has 
raised interest in NGS-based panel ctDNA assays, with the potential to detect a wide 
range of simple and complex genomic events, including targetable gene 
rearrangements (e.g., ALK and ROS1). 60,61 Determination of clinical validity for these 
broad NGS-based approaches is challenging, given that they generally target multiple 
tumor types. Initial studies seem to demonstrate similar overall concordance with tissue-
based genotyping as PCR-based assays, though concordance may be reduced for 
variants found in ctDNA at a low variant allele fractions (<1%). 62  
Advanced cancers may be genetically heterogeneous and this presents a 
potential challenge to ctDNA testing, in particular as the ctDNA assays may sample 
tumor DNA arising from all sites of metastasis, whereas tissue genotyping is conducted 
on a biopsy of a single metastatic site or on the archival primary (refer to Figure 2). High 
sensitivity ctDNA assays may detect sub-clonal variants, and such sub-clonal variants 
may theoretically not predict for durable responses to therapies that target the variant. 
The extent of the sub-clonality likely differs depending on the variant, whether the 
variant can be selected by prior therapy, and the patient population. For example, 
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genetic heterogeneity likely does not appreciably affect the utility of ctDNA testing for 
EGFR activating variants in therapy naïve advanced lung cancer, as the variants are 
rarely sub-clonal. The extent to which genetic heterogeneity affects the utility of ctDNA 
testing for treatment selected T790M EGFR variants, where variants may be sub-clonal, 
has not been robustly established in the literature. Limited current data suggest that the 
incidence of sub-clonal T790M EGFR variants is sufficiently low, with the studied PCR 
assay, to not effect utility. 30 Further research is required to assess for which variants, 
and in which contexts of testing, sub-clonality may undermine the clinical utility of ctDNA 
assays. 
 
Establishing Clinical Validity and Utility of ctDNA Assays 
Future research studies to establish clinical validity and utility of ctDNA assays 
should include a patient cohort that matches the intended use population as closely as 
possible and samples collected from a prospective study with defined entry criteria. 
Data will most frequently come from a phase II or phase III study in the patient 
population where it is anticipated the assay would be used in subsequent clinical 
practice, with the frequency of the variant under study approximately equal to that in an 
unselected clinical population. In prospective studies of targeted therapies, the entry 
criteria should allow inclusion of patients in which the variant under study is observed in 
the plasma, but not in the tissue analysis to evaluate the treatment response of this 
population with discordant genotyping results. 
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Evidence on the Use of ctDNA Assays for Noninvasive Monitoring of Advanced 
Cancer 
Another potential use for ctDNA assays is monitoring treatment effect, involving 
quantitative measurement of ctDNA over time, in response to cancer treatments. Blood-
based monitoring of treatment response and progression via ctDNA analysis is 
attractive since it is minimally invasive, does not involve ionizing radiation, and could 
ultimately be less expensive than current approaches to response assessment. Indeed, 
assays for tumor-associated proteins, such as CEA, PSA, CA125, MUC1, and CA19-9, 
are well-established in routine clinical care for patients with documented metastatic 
colorectal, prostate, ovarian, breast, and pancreatic cancers, respectively. 
However, validation of an assay quantitation of tumor burden is more technically 
challenging than an assay that merely dichotomizes patients into ctDNA variant 
detected or not detected. First, the efficiency and reproducibility of pre-analytic and 
analytic steps are critical to allow reliable quantitation of variant ctDNA. Compatibility 
and interoperability of results, in terms of the measured variant ctDNA load from 
different laboratories, will also be necessary. Quantitation needs to be uniform and 
reproducible between laboratories for results to be comparable within and between 
patients and to allow for results from different labs and trials to be comparable. 
Furthermore, the best unit for quantifying DNA burden is not established; most current 
approaches measure either the somatic variant allele frequency or detected somatic 
variant events per unit of plasma. 63,64 Since the former method is a ratio of somatic 
variant to non-variant ctDNA, it controls for the amount of plasma DNA input. However, 
this ratio could be affected by the levels of non-cancer origin cell-free DNA, which can 
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fluctuate over time, and may also conceivably be affected by certain therapies. The best 
approach to quantitation is currently unclear and will likely evolve in concert with what is 
needed for clinical utility and patient management. 
Correlations between changes in ctDNA levels and tumor responses or 
outcomes have been demonstrated in small proof of principle studies in a variety of 
cancer types such as lung cancer,  44,49,65 colorectal cancer, 66,67 breast cancer, 2,68, 
lymphoma 69,70, and melanoma.71 Additionally, studies of multiple cancer types indicate 
that ctDNA analysis can identify the emergence of resistant mutations months earlier 
than standard radiologic studies, 67,72,73 creating an opportunity to test whether changing 
therapy before clinical progression could improve outcomes. 74  
However, currently there is a lack of rigorous evidence on clinical validity let 
alone clinical utility, as few large, prospective validation studies have been performed 
on ctDNA-based monitoring. Published studies are mostly retrospective and few 
rigorous comparisons to established response metrics have been performed. 
Additionally, no studies convincingly demonstrate improved patient outcomes or any 
cost savings when compared to standard-of-care monitoring approaches. There is no 
evidence supporting changing treatment at the time of ctDNA progression before clinical 
progression. Finally, some data suggest that ctDNA responses do not always parallel 
imaging-based responses. 75 This could complicate validation of ctDNA-based 
monitoring and suggests that studies will need ultimately to assess clinical outcome in 
addition to correlation with radiographic responses. 
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Evidence on the Use of ctDNA Assays to Detect Residual Disease in Early Stage 
Cancer 
There is hope that ctDNA assays can be used for detection and monitoring of 
residual tumor after curative therapy for solid tumors, in the way that detection of 
leukemic cells in blood after completion of initial therapy (or minimal residual disease) 
has entered routine clinical practice in the management of leukemia.76  Circulating 
tumor DNA can be detected prior to treatment in patients with early stage primary 
cancer; however, ctDNA is generally detected at a lower rate than in advanced cancer. 
20,60,77 Persistent detection of ctDNA after local therapy (surgery or radical radiotherapy) 
predicts for a high risk of relapse in proof of principle studies in colon cancer, 63,64,78 
breast cancer, 79,80  pancreatic cancer, 81 and lung cancer 82. In these studies, the 
primary tumor is often sequenced to identify somatic genetic events that can then be 
tracked in plasma as evidence of residual disease. Evidence is lacking to demonstrate 
the ability of ctDNA assays to detect a similarly low level of residual disease that would 
correctly be referred to as minimal residual disease detection similar to the use of the 
term in leukemia management. 
Importantly, current studies are retrospective and findings have not been 
validated in prospective studies, providing limited evidence of clinical validity. No studies 
have systematically conducted imaging at the point of ctDNA detection to confirm that 
overt metastatic disease has not already developed at the point of ctDNA detection. The 
false negative rate of ctDNA analysis in this setting (patients who relapse without ctDNA 
being detected) and the false positive rate (patients who do not relapse despite the 
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ctDNA assay being positive), 83 have not been established sufficiently for any assay. 
Large, prospective studies are needed to establish clinical validity for this purpose.  
The theoretical potential of detection of residual disease in this fashion is that 
early treatment, triggered by changes in ctDNA, could eradicate residual disease and 
prevent or delay relapse. The clinical utility of such an approach has not been 
established; there is no evidence that treatment based upon the detection of ctDNA 
improves outcome. Indeed, prospective randomized trials of circulating protein markers 
have failed to demonstrate survival benefits from screening for occult recurrences in 
breast and ovary cancers, although there are data to suggest they are helpful in 
colorectal and prostate cancers. 84-88 Evidence of clinical utility can only be obtained 
from future prospective randomized studies. 
 
Evidence on the Use of ctDNA Assays in Screening for Cancer in Asymptomatic 
Individuals 
Given that ctDNA can be detected in some patients diagnosed with early stage 
cancer, there is substantial interest in the potential of using ctDNA in early detection of 
cancer in asymptomatic individuals and populations. Case reports of detection of cancer 
during maternal cell-free DNA testing, to detect fetal DNA aneuploidy, raise the potential 
of this approach. 89 However, at this time there are no data on clinical validity in this 
setting, and no evidence of clinical utility. The extent to which assays may have false 
positive test results (both technical and biological), diagnosing the presence of cancer in 
a patient without cancer, and determining tissue of origin, have not been established. It 
is also possible that circulating genomic variants could arise in cells that have taken the 
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first step towards transformation, but were never destined to become clinically 
important. This form of biologic false positive, commonly termed “over-diagnosis” has 
been well documented in breast cancer with mammographic screening 90 and prostate 
cancer with PSA screening. 91 
Although assays detection of viral DNA inserted into cancer DNA were not 
reviewed in this statement, an important prospective study has demonstrated the 
potential of screening for nasopharyngeal carcinoma in China; a ctDNA assay for 
Epstein-Barr virus (EBV) DNA detected early stage cancers with a positive predictive 
value of 11%. 92 While this study highlights the potential of ctDNA analysis for cancer 
screening, the analytical challenges of detecting a non-human genome like EBV are 
substantially different from common solid tumor early detection. At present, there is no 





Circulating tumor DNA assays could play a future role in the management of 
patients with cancer. Despite the extremely high level of current enthusiasm, 
deployment of ctDNA assays in routine clinical practice requires evidence of clinical 
utility. There is little evidence of clinical validity and clinical utility to support widespread 
use of ctDNA assays in most patients with advanced cancer, with the exception of those 
with demonstrated clinical utility or those with regulatory approval. The increasing 
uptake of ctDNA assays in clinical care highlights the clear demand to inform clinical 
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decision-making. Robust research is needed in several areas, as discussed in this 
manuscript, in order to enable development of clinical practice recommendations. 
Tumor genotyping is a rapidly evolving area of research in many areas of cancer care. 
Over time, it is highly likely that evidence will emerge to enable better assessment of the 
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Total amount of cell-free DNA in plasma or serum, which can be 




The fraction of cell-free DNA that originates from tumor cells. The 
presence of ctDNA in cell-free DNA is generally inferred by the 
detection of somatic variants; consequently, the presence of ctDNA 
in cell-free DNA is usually not confirmed until after a ctDNA assay 
is performed. 
ctDNA assay A clinical test designed to detect somatic variants in ctDNA. This 
encompasses targeted assays that may interrogate a single variant 
in one gene to broad assays that may interrogate numerous 
variants in many genes. Other terms for ctDNA assays include 
circulating cell-free plasma DNA assays and plasma genotyping 
assays. 
Liquid biopsy A broad category for a minimally invasive test done on a sample of 
blood to look for cancer cells from a tumor that are circulating in the 
blood or for fragments of tumor-derived DNA that are in the blood. 
Tumor genetics or genomics from ctDNA assays are one example. 
Variant allele 
fraction 
The fraction of alleles in a specimen that contain the variant, or 
mutation. As an example, a pure population of tumor cells in which 
one allele contained a BRAF V600E variant and the other BRAF 
allele was wild type (i.e., not variant/mutated) would have a BRAF 
V600E variant allele fraction of 50%. 
Pre-
analytical 
Issues regarding collection, handling, transport, processing, and 




Ability of an assay to detect and measure, with statistical 
significance, the presence of a biomarker of interest accurately, 
reproducibly, and reliably. 
Clinical 
validity 
Ability of an assay to divide, with statistical significance, one 
population into two or more groups based on outcomes, such as 
presence of cancer or treatment response. 
Clinical utility Ability to demonstrate, with statistical significance, improvement in 
the diagnosis, treatment, management, or prevention of cancer, 
with the use of the assay compared to not using the assay. 
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Table 2: Summary of Key Findings on the Use of Circulating Tumor DNA Analysis 
in Patients with Cancer 
 





 Evidence suggests that plasma is the optimal specimen type for 
ctDNA analysis. 
 Evidence supports the use of either cell stabilizing tubes or EDTA 
anti-coagulant tubes. However, EDTA tubes need to be 
processed as expediently as possible within 6 hours of collection. 
Leukocyte stabilization tubes allow up to 48 hours from collection 
to processing, and longer with some tubes. 
 Further studies are required to address other pre-analytical 
variables that may impact ctDNA testing, including specimen 
collection, handling variables, storage condition and time, and 
patient-related biologic factors. 
Analytical 
Validity 
 Analytical validity needs to be clearly established for any clinical 
ctDNA assay, with particular attention paid to detection of variants 
near the reported lower limit of detection of the assay. Ideally, 
validation will include evaluation of standardized samples that 
facilitate cross-assay comparisons.   
 Evidence has not established optimal lower limits of detection for 
various types of somatic variants. Optimal lower limits of 
detection may vary depending on the intended use of the ctDNA 
assay, but are lower than for tumor genotyping assays. 
 Different ctDNA assays may not give the same results due to 
different assay performance characteristics, such as differing 
limits of detection.  
 Future studies should focus on cross-assay comparisons, assay 





 Evidence demonstrates the importance of integrating clinical 
information, and available information from tumor analysis, with 
the identification of an actionable somatic variant in a ctDNA 
assay, in order to inform the appropriate selection of therapy. 
 The proportion of ctDNA as a fraction of total cell free DNA in 
plasma varies substantially between different patients, and the 
potential prognostic and therapeutic implications of variant allele 
fractions from ctDNA assays need further study. 
 Caution is important when interpreting ctDNA variants found in 
genes that are mutated in Clonal Hematopoiesis of Indeterminate 
Potential (CHIP).  Additional research is necessary to determine 
how to interpret and report variants in these genes. 
 ctDNA assays in which a somatic variant is or is not identified, 
should be reported in a way that conveys the potential for 
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Topic Key Findings 





 Aside from assays that have received regulatory approval, most 
assays have insufficient evidence to demonstrate clinical validity, 
and most have no evidence of clinical utility. Well-designed 
clinical trials or equivalence studies are needed to demonstrate 
clinical utility for most assays. 
 Evidence shows discordance in results between ctDNA assays 
and tumor tissue genotyping and supports value of tumor tissue 
genotyping to confirm undetected ctDNA findings.  
 For advanced cancer, the evidence indicates that more reliable 
test results occur when the ctDNA assay is performed at the time 
of disease progression and not when responding to prior therapy. 
 There is evidence that positive findings from well-validated ctDNA 
assays may support initiation of a targeted therapy option where 
an assay for the relevant genomic marker has demonstrated 
clinical utility when performed in tissue. 
 For monitoring therapy effectiveness, evidence of clinical validity 
is still emerging and there is currently no evidence for clinical 
utility to suggest that ctDNA assays are useful in this context, 
outside of a clinical trial. 
 For early stage cancer, evidence of clinical validity is still 
emerging and there is currently no evidence of clinical utility to 
suggest that ctDNA assays are useful at diagnosis nor in the 
adjuvant setting after completing treatment, outside of a clinical 
trial. 
 For cancer screening, there is no evidence of clinical validity and 
clinical utility to suggest that ctDNA assays are useful in this 
context, outside of a clinical trial. 
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Table 3. Comparison of ctDNA vs Tumor Tissue Testing 
 
 
Considerations ctDNA Assay Tissue Assay 
Logistics  Easy to draw  Invasive, more challenging to 
obtain 
  Variable venipuncture risks  Variable biopsy risks 
  Easy serial testing  Serial testing more difficult 
Biology  Cannot directly correlate 
ctDNA results with histology or 
cellular phenotype 
 More likely to represent whole 
tumor but differential tumor cell 
turnover may bias 
representation 
 Can correlate with histology 
and cellular phenotype 
 Represents one small tumor 
region 
Pre-analytical  Easier to standardize across 
sites 
 Requires special processing 
and handling unless using cell 
stabilization tubes 
 Limited data on confounding 
patient-related factors 
 More difficult to standardize 
across sites 
 Utilizes existing, validated 
tissue processing and 
handling approaches  
Clinical Utility  Limited evidence for treatment 
selection in advanced cancer 
 No evidence for other potential 
indications 
 Substantial evidence for 
treatment selection in 
multiple malignancies for 
early and advanced cancers 
 
  
ASCO-CAP Joint Review on Circulating Tumor DNA in Patients with Cancer    
 
 
 Page 33 of 41 
Figure 1. Reflex tumor biopsy testing in patients with negative liquid biopsy 
results 
 
The evidence indicates that current liquid biopsy assays have sub-optimal sensitivity, 
and have an appreciable rate of discordance with tumor tissue genotyping. There are 
two potential reasons for a “not detected” ctDNA result – no variant in the tumor or the 
variant is present in the tumor tissue but not detected by the ctDNA assay. A diagnostic 
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Figure 2. Overlap between tissue and circulating tumor DNA genotyping in 
advanced cancer93 
 
The box represents a cohort of patients genotyped with tissue tumor and plasma ctDNA 
assays, many of whom will be undetected with both assays. For patients with mutation 
detected in tissue (blue circle) or ctDNA (gold circle), most are expected to have 
concordant tissue and ctDNA results. Discordant tissue and ctDNA genotyping results 
are most commonly due to the low sensitivity of ctDNA assays in tumors with low 
shedding of DNA into the blood. These tissue-positive, ctDNA-undetected cases would 
be expected to potentially respond to matched targeted therapy. Discordance with 
tissue-undetected, ctDNA-positive results, is most likely to result from either temporal 
heterogeneity (an archival tumor specimen) or spatial heterogeneity (a sub-clonal 
mutation), or assay error (false negative tissue genotyping or false positive ctDNA 
genotyping). Clonal Hematopoiesis of Indeterminate Potential may cause discordance 
from some mutations.  
 
   
Oxnard GR: First validation, then discovery: Establishing truth from cfDNA 
genotyping. Presented at the American Association for Cancer Research Annual 
Meeting, Washington, D.C., April 4, 2017 
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